[Skip to Content]
[Skip to Content Landing]
Editorial
May 24, 2010

A Curious Case of β-Blockers in Chronic Obstructive Pulmonary Disease

Author Affiliations

Author Affiliations: Department of Medicine, University of British Columbia, and the Providence Heart and Lung Institute, Vancouver, Canada.

Arch Intern Med. 2010;170(10):849-850. doi:10.1001/archinternmed.2010.97

β-Blockers are highly efficacious in the treatment of congestive heart failure and ischemic coronary syndromes and can reduce the total mortality of patients with these disorders by 30% to 40%.1 However, their use is frequently withheld inpatients who have coexisting chronic obstructive pulmonary disease (COPD) because clinicians fear that β-blockers will provoke bronchospasm and induce respiratory failure in these patients. Not surprisingly, large epidemiological studies have shown that fewer than one-third of patients with COPD receive β-blockers after an acute coronary event2 despite compelling data that they prolong life and improve health outcomes in such patients.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×